CVS

Business Context and Reporting Period

Company: CVS Corporation (now CVS Health Corp)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Thirteen and twenty-six weeks ended July 2, 2005
Business Overview: The largest retail pharmacy in the U.S. by store count, operating 5,439 retail and specialty pharmacy stores across 36 states and D.C. The company operates two segments: Retail Pharmacy and Pharmacy Benefit Management (PBM). A significant event during the period was the integration of the Eckerd Corporation acquisition (closed July 31, 2004), which added 1,268 stores and PBM assets.

Key Financial Metrics

Note: Total debt includes $875.0M short-term debt, $338.1M current portion of long-term debt, and $1,629.7M long-term debt.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 31.4% for the quarter and 33.0% for the six-month period compared to the prior year. This growth was significantly driven by the inclusion of Eckerd Corporation sales. Excluding acquired businesses, organic sales growth was approximately 7.9% for the quarter and 9.1% for the six months.
• Profitability: Net earnings rose 17.6% for the quarter and 18.0% for the six months. Operating profit increased 23.4% for the quarter and 23.3% for the six months.
• Expense Pressure: Total operating expenses increased 34.8% for the quarter. As a percentage of sales, operating expenses rose to 21.3% (from 20.7% prior year) due to lower average sales per store in the acquired portfolio and higher labor costs associated with integration.
• Interest Expense: Net interest expense surged to $28.3M for the quarter (from $6.0M prior year) and $56.3M for the six months (from $13.8M), driven by debt incurred to fund the Eckerd acquisition.
• Stock Split: A two-for-one common stock split was effected on June 6, 2005. All per-share data in the filing has been restated to reflect this split.

Guidance, Outlook, and Risks

• Store Development: The company opened 103 new stores and relocated 75 stores in the first six months of 2005. Management plans to open 120-125 new or relocated stores for the remainder of the fiscal year.
• Liquidity: Management anticipates cash flows from operations, commercial paper, and long-term borrowings will fund growth. The company maintains $1.325 billion in unsecured back-up credit facilities with no outstanding borrowings as of July 2, 2005.
• Key Risks:
  • Reimbursement Rates: Continued pressure from third-party payers (HMOs, PBMs, government) to reduce drug costs and reimbursement rates.
  • Mail Order Shift: Growth of mail-order channels and plan designs requiring exclusive mail-order fulfillment for maintenance drugs.
  • Integration: Risks associated with successfully integrating the Eckerd acquisition and realizing projected cost savings.
  • Legal Proceedings: Ongoing securities litigation (In re CVS Corporation Securities Litigation) and ERISA actions, though settlements are preliminarily approved and largely covered by insurance.
• Unusual Items: The filing notes that the Easter holiday occurred earlier in 2005 (March 27) than in 2004 (April 11), negatively impacting front-store same-store sales in the second quarter by shifting sales to the first quarter.

Investor Verification Checklist

• Organic Growth Rate: Verify the sustainability of the ~8-9% organic sales growth excluding the Eckerd acquisition impact.
• Integration Costs: Monitor the trajectory of operating expenses as a percentage of sales to ensure integration costs do not permanently erode margins.
• Debt Service: Assess the impact of the increased interest expense ($56.3M for six months) on future free cash flow.
• Legal Settlements: Confirm the final court approval and total cost of the securities and ERISA litigation settlements.
• Store Relocation Strategy: Evaluate the performance of relocated stores to validate the strategy of moving to freestanding locations.